Inserm U1082, Poitiers, F-86000, France.
Université de Poitiers, Faculté de Médecine et de Pharmacie, Poitiers, F-86000, France.
Biomed Res Int. 2018 Dec 4;2018:9206257. doi: 10.1155/2018/9206257. eCollection 2018.
Despite the fact that a significant fraction of kidney graft dysfunctions observed after transplantation is due to ischemia-reperfusion injuries, there is still no clear consensus regarding optimal kidney preservation strategy. This stems directly from the fact that as of yet, the mechanisms underlying ischemia-reperfusion injury are poorly defined, and the role of each preservation parameter is not clearly outlined. In the meantime, as donor demography changes, organ quality is decreasing which directly increases the rate of poor outcome. This situation has an impact on clinical guidelines and impedes their possible harmonization in the transplant community, which has to move towards changing organ preservation paradigms: new concepts must emerge and the definition of a new range of adapted preservation method is of paramount importance. This review presents existing barriers in transplantation (e.g., temperature adjustment and adequate protocol, interest for oxygen addition during preservation, and clear procedure for organ perfusion during machine preservation), discusses the development of novel strategies to overcome them, and exposes the importance of identifying reliable biomarkers to monitor graft quality and predict short and long-term outcomes. Finally, perspectives in therapeutic strategies will also be presented, such as those based on stem cells and their derivatives and innovative models on which they would need to be properly tested.
尽管移植后观察到的肾功能障碍很大一部分是由于缺血再灌注损伤引起的,但对于最佳的肾脏保存策略仍没有明确的共识。这直接源于这样一个事实,即迄今为止,缺血再灌注损伤的机制仍未得到明确界定,每个保存参数的作用也没有明确阐述。与此同时,由于供体人群的变化,器官质量下降,这直接增加了不良结果的发生率。这种情况对临床指南产生了影响,并阻碍了它们在移植界的可能协调,因为移植界必须转向改变器官保存模式:必须出现新的概念,定义新的适应保存方法范围至关重要。本综述介绍了移植中存在的障碍(例如,温度调节和适当的方案、在保存过程中添加氧气的兴趣以及在机器保存期间进行器官灌注的明确程序),讨论了开发克服这些障碍的新策略的必要性,并强调了确定可靠生物标志物来监测移植物质量和预测短期和长期结果的重要性。最后,还将介绍治疗策略的前景,例如基于干细胞及其衍生物的策略,以及需要对其进行适当测试的创新模型。